Nektar Therapeutics (NKTR)
NASDAQ: NKTR · Real-Time Price · USD
38.87
-0.31 (-0.79%)
At close: Oct 30, 2026, 4:00 PM EDT
38.50
-0.37 (-0.95%)
After-hours: Oct 30, 2026, 7:30 PM EDT
Nektar Therapeutics Stock Forecast
Stock Price Forecast
According to 15 analysts polled by S&P Global, Nektar Therapeutics stock has a consensus rating of "Buy" and an average price target of $133.08. The average 1-year stock price forecast is 242.37% higher than the current stock price, while the lowest is $50 (+28.63%) and the highest is $192 (+393.95%).
Price Target: $133.08 (+242.37%)
Analyst Consensus: Buy
Price Target
ChartAnalyst Ratings
The average analyst rating for Nektar Therapeutics stock is "Buy". This means that analysts believe this stock is likely to outperform the market over the next twelve months.
Recommendation Trends
| Rating | May '26 | Jun '26 | Jul '26 | Aug '26 | Sep '26 | Oct '26 |
|---|---|---|---|---|---|---|
| Strong Buy | 8 | 8 | 9 | 9 | 9 | 10 |
| Buy | 1 | 1 | 1 | 1 | 1 | 1 |
| Hold | 1 | 1 | 1 | 2 | 2 | 4 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 10 | 10 | 11 | 12 | 12 | 15 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Piper Sandler | Piper Sandler | Buy Maintains $192 | Buy | Maintains | $192 | +393.95% | Oct 22, 2026 |
| Leerink Partners | Leerink Partners | Buy Initiates $130 | Buy | Initiates | $130 | +234.45% | Oct 12, 2026 |
| UBS | UBS | Hold Initiates $53 | Hold | Initiates | $53 | +36.35% | Oct 12, 2026 |
| BTIG | BTIG | Buy Maintains $178 | Buy | Maintains | $178 | +357.94% | Oct 9, 2026 |
| Raymond James | Raymond James | Hold Initiates n/a | Hold | Initiates | n/a | n/a | Oct 8, 2026 |
Financial Forecast
Revenue This Year
41.82M
from 55.23M
Decreased by -24.28%
Revenue Next Year
53.42M
from 41.82M
Increased by 27.72%
EPS This Year
-8.26
from -8.66
EPS Next Year
-10.30
from -8.26
EPS and Forward PE are based on non-GAAP adjusted numbers.